Literature DB >> 16705192

Anti-myelin antibodies in multiple sclerosis: clinically useful?

C H Polman, J Killestein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16705192      PMCID： PMC2077472          DOI： 10.1136/jnnp.2006.089839

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  6 in total

1.  Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event.

Authors:  S Rauer; B Euler; M Reindl; Th Berger
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06       Impact factor: 10.154

2.  Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.

Authors:  Thomas Berger; Paul Rubner; Franz Schautzer; Robert Egg; Hanno Ulmer; Irmgard Mayringer; Erika Dilitz; Florian Deisenhammer; Markus Reindl
Journal:  N Engl J Med       Date:  2003-07-10       Impact factor: 91.245

3.  Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects.

Authors:  V Lampasona; D Franciotta; R Furlan; S Zanaboni; R Fazio; E Bonifacio; G Comi; G Martino
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

4.  Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis.

Authors:  Patrice H Lalive; Til Menge; Cecile Delarasse; Bruno Della Gaspera; Danielle Pham-Dinh; Pablo Villoslada; H-C von Büdingen; Claude P Genain
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

5.  Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association.

Authors:  Renato Mantegazza; Piercarlo Cristaldini; Pia Bernasconi; Fulvio Baggi; Rosetta Pedotti; Ilaria Piccini; Nerina Mascoli; Loredana La Mantia; Carlo Antozzi; Ornella Simoncini; Ferdinando Cornelio; Clara Milanese
Journal:  Int Immunol       Date:  2004-04       Impact factor: 4.823

6.  Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis.

Authors:  E T Lim; T Berger; M Reindl; C M Dalton; K Fernando; G Keir; E J Thompson; D H Miller; G Giovannoni
Journal:  Mult Scler       Date:  2005-08       Impact factor: 6.312
  6 in total
  3 in total

1.  A sensitive and selective ELISA methodology quantifies a demyelination marker in experimental and clinical samples.

Authors:  Albert G Remacle; Jennifer Dolkas; Mila Angert; Swathi K Hullugundi; Andrei V Chernov; R Carter W Jones; Veronica I Shubayev; Alex Y Strongin
Journal:  J Immunol Methods       Date:  2018-02-08       Impact factor: 2.303

Review 2.  The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis.

Authors:  Giuseppe Faraco; Leonardo Cavone; Alberto Chiarugi
Journal:  Mol Med       Date:  2011-02-25       Impact factor: 6.354

3.  The Role of Alpha-Synuclein Autoantibodies in the Induction of Brain Inflammation and Neurodegeneration in Aged Humans.

Authors:  Manoj Kumar Pandey
Journal:  Front Aging Neurosci       Date:  2022-05-26       Impact factor: 5.702
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.